KANSAS CITY, Mo., Nov. 16, 2026 (GLOBE NEWSWIRE) -- CRB, a global provider of engineering, architecture, construction and consulting solutions, announced today Ashley Harp, Fellow, Containment & Bioconjugates, has published a peer-reviewed article in AAPS PharmSciTech, an official journal of the American Association of Pharmaceutical Scientists (AAPS). It examines what manufacturers need to consider as antibody-drug conjugates (ADCs) move toward commercial production.
The article, “Antibody-Drug Conjugate Manufacturing: Facility Design, Process Safety, and Regulatory Considerations” examines manufacturing, formulation and fill/finish challenges associated with ADCs. It pays particular attention to cytotoxic products and the risks they present to personnel, facilities and the environment.
The article also covers regulatory expectations, including EU GMP Annex 1, and strategies to prevent cross-contamination and personnel exposure.
“ADC manufacturing presents a unique set of challenges because it requires the integration of highly potent compounds with complex biologic processes, each bringing its own safety, containment and regulatory considerations,” stated Harp. “As interest in these therapies continues to grow, manufacturers need to think holistically about process design, facility requirements and risk mitigation from the outset. My goal with this paper was to help clarify these considerations and provide a framework for approaching ADC manufacturing safely and compliantly.”
The publication comes as demand for that expertise is growing. CRB's Horizons: Life Sciences 2026 report, based on insights from more than 400 global life science leaders, found that every modality tracked in the survey, including ADCs, saw increased manufacturing interest compared with 2025. The report also highlights the industry's focus on improving manufacturing efficiency, managing workforce constraints and investing in facilities and technologies that can support long-term growth. As ADC pipelines advance, manufacturers will need to align facility investments with both current production requirements and future portfolio needs.
Key considerations covered in the article include:
- Containment and personnel protection: Evaluating process-specific risks and applying appropriate containment strategies to limit exposure to cytotoxic compounds.
- Facility and equipment design: Building risk mitigation into layouts, equipment selection and workflows.
- Cross-contamination prevention: Using holistic design and operational strategies to protect product quality, personnel and the environment.
- Regulatory readiness: Aligning facility design and manufacturing planning with applicable GMP requirements, including EU GMP Annex 1.
Read the full review, “Antibody-Drug Conjugate Manufacturing: Facility Design, Process Safety, and Regulatory Considerations”, in AAPS PharmSciTech: https://link.springer.com/article/10.1208/s12249-026-03502-7.
About Horizons: Life Sciences
Published annually by CRB, Horizons: Life Sciences explores the trends shaping the future of pharmaceutical and biotechnology manufacturing. The 2026 report is based on insights from more than 400 life science leaders across North America, Europe and multinational organizations. It examines the factors influencing facility investment, pipeline growth, manufacturing innovation and workforce strategy.
About CRB
CRB partners with life science and food & beverage companies to design, build and optimize the facilities where innovative therapies, medicines and consumer products are developed and manufactured. Through an integrated approach that combines engineering, architecture, construction and consulting expertise, CRB helps clients navigate complex projects and deliver sustainable solutions from concept to operation and optimization with confidence. Learn more at crbgroup.com and follow CRB on LinkedIn.
Attachment